Liquid biopsy in hepatocellular carcinoma: Challenges, advances, and clinical implications
- Author:
Jaeho PARK
1
;
Yi-Te LEE
;
Vatche G. AGOPIAN
;
Jessica S LIU
;
Ekaterina K. KOLTSOVA
;
Sungyong YOU
;
Yazhen ZHU
;
Hsian-Rong TSENG
;
Ju Dong YANG
Author Information
- Publication Type:Review
- From:Clinical and Molecular Hepatology 2025;31(Suppl):S255-S284
- CountryRepublic of Korea
- Language:English
- Abstract: Hepatocellular carcinoma (HCC) is an aggressive primary liver malignancy often diagnosed at an advanced stage, resulting in a poor prognosis. Accurate risk stratification and early detection of HCC are critical unmet needs for improving outcomes. Several blood-based biomarkers and imaging tests are available for early detection, prediction, and monitoring of HCC. However, serum protein biomarkers such as alpha-fetoprotein have shown relatively low sensitivity, leading to inaccurate performance. Imaging studies also face limitations related to suboptimal accuracy, high cost, and limited implementation. Recently, liquid biopsy techniques have gained attention for addressing these unmet needs. Liquid biopsy is non-invasive and provides more objective readouts, requiring less reliance on healthcare professional’s skills compared to imaging. Circulating tumor cells, cell-free DNA, and extracellular vesicles are targeted in liquid biopsies as novel biomarkers for HCC. Despite their potential, there are debates regarding the role of these novel biomarkers in the HCC care continuum. This review article aims to discuss the technical challenges, recent technical advancements, advantages and disadvantages of these liquid biopsies, as well as their current clinical application and future directions of liquid biopsy in HCC.
